Full Text View
Tabular View
No Study Results Posted
Related Studies
Diffusion Tensor Imaging (DTI) in Infants With Krabbe Disease
This study is currently recruiting participants.
Verified by National Institute of Neurological Disorders and Stroke (NINDS), December 2008
First Received: November 7, 2008   Last Updated: December 1, 2008   History of Changes
Sponsors and Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
New York State Department of Health
Hunter's Hope
Information provided by: National Institute of Neurological Disorders and Stroke (NINDS)
ClinicalTrials.gov Identifier: NCT00787865
  Purpose

This study is designed to learn about early brain development in children with Krabbe disease, and to use diffusion tensor imaging as an early diagnostic tool to identify newborns at risk for the disease.


Condition
Krabbe Disease

Genetics Home Reference related topics: Chanarin-Dorfman syndrome cholesteryl ester storage disease Farber lipogranulomatosis Krabbe disease leukoencephalopathy with vanishing white matter long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency megalencephalic leukoencephalopathy with subcortical cysts mitochondrial trifunctional protein deficiency primary carnitine deficiency succinic semialdehyde dehydrogenase deficiency
MedlinePlus related topics: Leukodystrophies
U.S. FDA Resources
Study Type: Observational
Study Design: Case Control, Prospective
Official Title: Diffusion Tensor Imaging (DTI) as a Tool to Identify Infants With Krabbe Disease in Urgent Need of Treatment

Further study details as provided by National Institute of Neurological Disorders and Stroke (NINDS):

Primary Outcome Measures:
  • Diffusion tensor imaging (DTI) of corticospinal tracts [ Time Frame: at birth, 1 year and 2 years of age ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Motor development at birth, 1 year and 2 years of age [ Time Frame: at birth, 1 year and 2 years of age ] [ Designated as safety issue: No ]
  • Analysis of DTI-Fractional Diffusion Anisotropy (FA) values of corticospinal tracts of newborns [ Time Frame: at age (newborn-6 weeks), 12-months and 24-months ] [ Designated as safety issue: No ]

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 100
Study Start Date: April 2008
Estimated Study Completion Date: April 2013
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Krabbe disease
children with infantile Krabbe disease
Low enzyme/no Krabbe disease
children without disease who have low enzyme levels
Control
children with no disease and normal enzyme levels

Detailed Description:

This study is designed to learn about early brain development in children with Krabbe disease and to use diffusion tensor imaging (DTI) as an early diagnostic tool to differentiate children with infantile Krabbe disease from newborns who are disease free but have very low enzyme levels.

Additionally, this study will determine how certain structures in the brain will develop over 24 months in children with infantile Krabbe disease and those without disease who have low enzyme levels. This study will also reveal information about the learning and motor development of children, and will help researchers predict outcomes after treatment.

Krabbe disease is a rare, childhood neurodegenerative disorder caused by galactocerebrosidase deficiency. It results in rapid demyelination, progressive spasticity, mental deterioration, blindness, deafness, seizures, and death. Based on previously published findings, treatment with unrelated umbilical cord blood transplantation is now standard for Krabbe disease, provided that the treatment occurs within the first weeks of life and before symptoms appear.

Once newborns are identified through population screening, there is no objective measure to predict if the baby will develop the most frequent rapidly progressive infantile forms of Krabbe or have a slower juvenile or adult form. Phenotype and genotype correlations are not possible because there are more that 75 mutations that can cause the disease and many polymorphisms in the normal population that affect the enzyme level.

There is an urgent clinical need to develop a predictive measure. However, to date, there are no available tools to classify infants into the infantile versus later forms. New advances in neuroimaging techniques have enabled scientists to quantify changes in brain growth and myelination early in life and before disease symptoms develop.

Knowledge from this study will help identify the window of opportunity for early intervention and treatment to prevent severe disability, and may lead to better treatment strategies.

  Eligibility

Ages Eligible for Study:   up to 2 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Children with a low galactocerebrosidase level at birth, with a family history of Krabbe disease or that have been diagnosed with infantile Krabbe disease because of symptoms. Newborn screening State of New York and newborns with low enzyme identified through the Lysosomal Storage Disorders Laboratory at Thomas Jefferson University.

Criteria

Inclusion Criteria:

  • Infants with a galactocerebrosidase level <12 percent of the daily mean

Exclusion Criteria:

  • Congenital anomalies
  • Other neurological diagnoses
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00787865

Contacts
Contact: Jim Kenny 919-966-6312 Jim.kenny@cdl.unc.edu
Contact: Betsy M Glaser, PNP 919-966-4810 Betsy.glaser@cdl.unc.edu

Locations
United States, North Carolina
University of North Carolina Recruiting
Chapel Hill, North Carolina, United States, 27517
Contact: Jim Kenny     919-966-6113     Jim.kenny@cdl.unc.edu    
Contact: Diana J Dalsimer, BS     919-966-4809     Diana.dalsimer@cdl.unc.edu    
Principal Investigator: Maria L Escolar, MD, MS            
Sponsors and Collaborators
New York State Department of Health
Hunter's Hope
Investigators
Principal Investigator: Maria L Escolar, MD, MS Director for the Program of Neurodevelopmental Function in Rare Disorders, the University of North Carolina at Chapel Hill
Investigator: Martin Styner, PhD University of North Carolina at Chapel Hill, Co-Investigator
Investigator: Michele Poe, PhD University of North Carolina at Chapel Hill, Co-Investigator
  More Information

Additional Information:
Publications:
Responsible Party: University of North Carolina at Chapel Hill ( Maria Luisa Escolar, MD, MS, Director for the Program of Neurodevelopmental Function in Rare Disorders )
Study ID Numbers: R01NS061965, 1R01NS061965-01
Study First Received: November 7, 2008
Last Updated: December 1, 2008
ClinicalTrials.gov Identifier: NCT00787865     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institute of Neurological Disorders and Stroke (NINDS):
diffusion tension imaging
DTI
newborn
Krabbe disease
motor development

Study placed in the following topic categories:
Lipid Metabolism, Inborn Errors
Sphingolipidoses
Metabolic Diseases
Demyelinating Diseases
Lysosomal Storage Diseases
Sphingolipidosis
Central Nervous System Diseases
Brain Diseases
Leukodystrophy
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Brain Diseases, Metabolic, Inborn
Lipidoses
Metabolic Disorder
Leukodystrophy, Globoid Cell
Krabbe Leukodystrophy
Lipid Metabolism Disorders
Brain Diseases, Metabolic

Additional relevant MeSH terms:
Lipid Metabolism, Inborn Errors
Sphingolipidoses
Metabolic Diseases
Demyelinating Diseases
Lysosomal Storage Diseases, Nervous System
Lysosomal Storage Diseases
Nervous System Diseases
Central Nervous System Diseases
Brain Diseases
Hereditary Central Nervous System Demyelinating Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Brain Diseases, Metabolic, Inborn
Lipidoses
Leukodystrophy, Globoid Cell
Lipid Metabolism Disorders
Brain Diseases, Metabolic

ClinicalTrials.gov processed this record on May 07, 2009